FDA Analysis Concludes No Unexpected Safety Risks Associated With Pimavanserin

FDA Analysis Concludes No Unexpected Safety Risks Associated With Pimavanserin  Pharmacy Times FDA clears Parkinson's disease drug from Acadia of new safety concerns  The San Diego Union-Tribune FDA: No Evidence Linking Pimavanserin to Parkinson Patient Deaths  MD MagazineFull coverage

(CLICK HERE TO READ AND SEE MORE)